Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg weekly) and dual incretin agonists (tirzepatide) significantly reduce hepatic steatosis and improve or resolve steatohepatitis (MASH) in patients with MASLD, primarily through sustained weight loss and improved insulin sensitivity.
If you have fatty liver disease linked to metabolic issues, GLP-1 medications like semaglutide are currently the most effective pharmacological tool to reverse liver inflammation and fat. They work by targeting the root metabolic causes rather than just the liver itself. Consult a doctor to see if you qualify for these treatments, especially if lifestyle changes alone haven't resolved your liver health markers.
In a Phase 3 trial, semaglutide 2.4 mg weekly achieved resolution of steatohepatitis without fibrosis worsening in 62.9% of patients compared with 34.3% with placebo... Dual incretin agonism with tirzepatide has demonstrated substantial weight loss of ~15%–22%, accompanied by marked improvements in insulin sensitivity and hepatic steatosis.
Why this rating
Supported by Phase 3 trials and imaging-based analyses, though definitive histology-based outcomes for tirzepatide are noted as ongoing.
Source
Obesity and Metabolic Dysfunction‐Associated Steatotic Liver Disease ( <scp>MASLD</scp> ): A Literature Review on Pathophysiology and Treatment
Michael Romanos et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70659
More from this paper
- Weight loss of 7-10% is required to resolve steatohepatitis (MASH) and regress fibrosis, whereas 5% loss primarily improves steatosis.Strong
- Lean MASLD (normal BMI but with metabolic dysfunction) is a distinct phenotype driven by sarcopenia, adverse fat distribution, and genetic susceptibility, requiring different treatment strategies than obesity-driven MASLD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →